



euroPLX

Business Developer

Vol. 15 # 6 | June | 2019

Mergers and Acquisitions Taking a Breather - or Summer Slowdown?

* Acquisition: **ANI Pharmaceuticals, Inc.** has acquired a pipeline of seven development stage generic products from **Coeptis Pharmaceuticals, Inc.** for \$2.3 million dollars in cash and up to \$12.0 million in additional development and commercial milestones. As part of the agreement, ANI will pay a portion of gross profit generated from one of the injectable products to the commercial manufacturing partner. 18 Jun 2019 (www.anipharmaceuticals.com)

* Divestment: **Biogen** has completed its acquisition of **Nightstar Therapeutics**, a clinical-stage gene therapy company, which is focused on adeno-associated virus treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. The total transaction value was approximately \$800 million, after taking into account expected transaction expenses and cash at closing. 7 Jun 2019 (www.biogen.com)

* Name change: **Blake Insomnia Therapeutics, Inc.** has completed the previously announced name change request to rebrand as **BioHemp International**. 18 Jun 2019 (www.biohempinternational.com/)

* Acquisition: **Boehringer Ingelheim** and the Danish biotech company **Gubra** announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales. 29 May 2019 (www.boehringer-ingelheim.com)

* Acquisition: **Catalent, Inc.**, has agreed to purchase **Bristol-Myers Squibb's** oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. 19 Jun 2019 (www.catalent.com)

* Name Change: **CollPlant**, a regenerative medicine company, has changed its corporate name from "**CollPlant Holdings Ltd.**" to "**CollPlant Biotechnologies Ltd.**" effective June 21, 2019. 20 Jun 2019 (www.collplant.com)

* Acquisition and Name Change: **CutisPharma, Inc.** acquired **Silvergate Pharmaceuticals, Inc.** and the combined companies will assume a new name: **Azurity Pharmaceuticals**. 12 Jun 2019 (cutispharma.com)

* Licensing: **Deciphera Pharmaceuticals, Inc.** and **Zai Lab Ltd.**, a

China and U.S.-based innovative biopharmaceutical company, signed an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFR. 11 Jun 2019 (www.deciphera.com)

* Acquisition: **Roche** and **Spark Therapeutics, Inc.** have each received a request for additional information and documentary material from the U.S. Federal Trade Commission in connection with the FTC's review of Roche's pending acquisition of gene therapy company Spark Therapeutics for more than \$4 billion. This is the fourth time the deadline has been extended, and with the third tender offer to expire June 14, the new deadline is now pushed back to July 31. 10 Jun 2019 (www.roche.com)

* Acquisition: **Kiadis Pharma N.V.** has closed the previously announced acquisition of **CytoSen Therapeutics, Inc.** 6 Jun 2019 (www.kiadis.com)

* Acquisition: **Lyophilization Services of New England, Inc.** announced the acquisition of a sterile injectables manufacturing facility located in León, Spain. The site, LSNE-León, will complement LSNE's existing full-service manufacturing capabilities and expand its reach into Europe. LSNE-León is located northwest of Madrid. 17 Jun 2019 (www.lyophilization.com)

* Acquisition: **Merck & Co., Inc.** has entered into a definitive agreement to acquire **Tilos Therapeutics**, a privately held biopharmaceutical company developing therapeutics targeting the latent TGF complex for the treatment of cancer, fibrosis and autoimmune diseases. Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Tilos for total potential consideration of up to \$773 million, including an upfront payment as well as contingent milestone payments. 10 Jun 2019 (www.merck.com)

* Acquisition: **Pfizer Inc.** and **Array BioPharma Inc.** have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat

cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for \$48 per share in cash, for a total enterprise value of approximately \$11.4 billion. 17 Jun 2019 (www.pfizer.com)

* Distribution: **Shionogi & Co., Ltd.** and **Molteni Farmaceutici** have signed an agreement for the distribution and sale of Rizmoic (naldemedine) in Italy and Poland. Shionogi will help promote the therapy. Rizmoic was recently approved in Europe for the treatment of opioid-induced constipation in adults previously treated with a laxative. 22 May 2019 (www.shionogi.co.jp)

* Acquisition: **Swedish Orphan Biovitrum AB** has signed an agreement to acquire, from **Novimmune's** shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the exclu-

sive licence agreement with Novimmune will be superseded. The consideration for the acquisition is CHF 515 M (SEK 4,897 M), of which CHF 400 M was previously committed in the exclusive licence agreement for emapalumab. 12 Jun 2019 (www.sobi.com)

* Acquisition: **Vertex Pharmaceuticals Inc.** is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1 by expanding its collaboration with CRISPR Therapeutics and acquiring **Exonics Therapeutics**. Vertex and CRISPR Therapeutics have expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of DMD and DM1. Vertex and Exonics Therapeutics have entered into a definitive agreement under which Vertex will acquire privately held Exonics, a company focused on creating

transformative gene editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases. 6 Jun 2019 (www.vrtx.com)

* Acquisition: **Zentiva Group a.s.** completed the previously announced acquisition of Romanian-based pharmaceutical company **Solacium Pharma**, together with its subsidiary, **Be Well Pharma**. The finalisation of this acquisition is assumed to play a key role in the long-term growth strategy of Zentiva. 31 May 2019 (www.zentiva.com)

* Spin-off: **Zinereo Pharma S.L.U.** has been formed as a spin-off from **Biofabri S.L.** with the aim to differentiate and combine the business units specialised in the development and manufacture of pharmaceutical products and probiotics. All necessary certificates of Health Authorities have been transferred to Zinereo as of April 2919. 11 June 2019 (www.zinereopharma.com)

BD People on the Move

* EirGen Pharma Ltd.: **Liam Byrne**, who has been Head of Business Development & Alliance Management, left the company effective 14 June, in order to pursue other opportunities (Pers Comm 21 May 2019)

* MedPharm: **Christian Hoenig**, who has been Business Development Manager, left to pursue other opportunities. (Pers Comm 23 May 2019)

* Xencor, Inc.: **Jeremy Grunstein**, Ph.D., who served in several strategic business development roles at Amgen Inc., has been appointed as vice president, business development. (Press Release 23 May 2019)

The Interactive Hub for Business Development

euroPLX is the world's most often held partnering conference for the pharma and biopharma industries.

Because of results delivered. Year-round.

Join the 71st International Partnering Conference for Pharma Business Development*

*euroPLX 71 Lisbon (Portugal)

November 25 + 26, 2019, Hotel Cascais Miragem, Cascais (near Lisbon)

euroPLX events are temporary interactive hubs for pharma business development. Running for several months on an online platform, they are complemented by personal meetings of the participating executives during a concluding two-days partnering conference.

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Register online: www.europlx.com

 **euroPLX**
by RauCon

www.europlx.com
meetyou@europlx.com
ph. ++49 (6221) 426296-0

The Original since 1995.
Often copied. Never equaled.

